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Abstract
Background: For ≈ 24 years the AIDS pandemic has claimed ≈ 30 million lives, causing ≈ 14,000
new HIV-1 infections daily worldwide in 2003. About 80% of infections occur by heterosexual
transmission. In the absence of vaccines, topical microbicides, expected to block virus transmission,
offer hope for controlling the pandemic. Antiretroviral chemotherapeutics have decreased AIDS
mortality in industrialized countries, but only minimally in developing countries. To prevent an
analogous dichotomy, microbicides should be: acceptable; accessible; affordable; and accelerative in
transition from development to marketing. Already marketed pharmaceutical excipients or foods,
with established safety records and adequate anti-HIV-1 activity, may provide this option.
Methods: Fruit juices were screened for inhibitory activity against HIV-1 IIIB using CD4 and
CXCR4 as cell receptors. The best juice was tested for inhibition of: (1) infection by HIV-1 BaL,
utilizing CCR5 as the cellular coreceptor; and (2) binding of gp120 IIIB and gp120 BaL, respectively,
to CXCR4 and CCR5. To remove most colored juice components, the adsorption of the effective
ingredient(s) to dispersible excipients and other foods was investigated. A selected complex was
assayed for inhibition of infection by primary HIV-1 isolates.
Results: HIV-1 entry inhibitors from pomegranate juice adsorb onto corn starch. The resulting
complex blocks virus binding to CD4 and CXCR4/CCR5 and inhibits infection by primary virus
clades A to G and group O.
Conclusion: These results suggest the possibility of producing an anti-HIV-1 microbicide from
inexpensive, widely available sources, whose safety has been established throughout centuries,
provided that its quality is adequately standardized and monitored.
Background
The global AIDS epidemic has proceeded relentlessly for ≈
24 years with no promising prophylactic intervention in
sight. In 2003 there were 5 million new HIV infections,
and 3 million AIDS deaths [1]. To date the number of
individuals living with HIV-1 infection/AIDS has reached
40 million, and ≈ 30 million people have already died
from AIDS since the beginning of the pandemic [1,2].
Most new infections have been acquired by the mucosal
route, heterosexual transmission playing the major (≈
80%) role. Although the incidence of transmission per
unprotected coital act is estimated to be low (0.0001 –
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0.004), but strikingly increased when acutely infected
individuals are involved [3,4], the cumulative effect is
overwhelming.
Anti-HIV-1 vaccines applicable to global immunization
programs are not expected to become available for many
years. Thus, other prevention strategies are urgently
needed. This includes educational efforts and application
of mechanical and/or chemical barrier methods. The latter
correspond to microbicides, i.e. topical formulations
designed to block HIV-1 infection (and possibly transmis-
sion of other sexually transmitted diseases) when applied
vaginally (and possibly rectally) before intercourse [3,5-
7]. Conceptually, it is preferred that the active ingredi-
ent(s) of microbicide formulations (1) block virus entry
into susceptible cells by preventing HIV-1 binding to the
cellular receptor CD4, the coreceptors CXCR4/CCR5 and
to receptors on dendritic/migratory cells (capturing and
transmitting virus to cells which are directly involved in
virus replication), respectively [3,8-11], and/or (2) are
virucidal. The formulations must not adversely affect the
target tissues, and should not cause them to become more
susceptible to infection after microbicide removal
[12,13].
Treatment with anti-retroviral drugs has decreased mortal-
ity from AIDS in industrialized countries but has had a
minimal effect so far in developing countries [14]. To
avoid a similar dichotomy with respect to microbicides,
they should be designed and selected to become afforda-
ble and widely accessible, while shortening the time
between research and development and their marketing
and distribution as much as possible. This would be facil-
itated if mass manufactured products with established
safety records were to be found to have anti-HIV-1 activ-
ity. Qualifying candidates to be considered for microbi-
cide development may possibly be discovered by
screening pharmaceutical excipients (= "inactive" ingredi-
ents of pharmaceutical dosage forms) and foods, respec-
tively, for anti-viral properties. This approach has already
led to the discovery of cellulose acetate 1,2-benzenedicar-
boxylate (used for coating of enteric tablets and capsules)
as a promising candidate microbicide [15-19]. Here we
report the outcome of screening fruit juices neutralized to
pH ≈ 7 to discount nonspecific effects caused by acidity.
Methods
Reagents
Pomegranate juices (PJ) were purchased in local New
York City stores; their origin is given in parentheses: PJ1
(Madeira Enterprises Inc., Madeira, CA); PJ2 was prepared
from fresh ripe pomegranates in our laboratory; PJ3
(Sadaf®; Sadaf® Foods, Los Angeles, CA; additional ingredi-
ents: fructose, citric acid); PJ4 (Cortas Canning & Refriger-
ation Co. S.A.L., Beirut, Lebanon); PJ5 (Kradjian, Import
& Wholesale Distribution, Glendale, CA. Product of Iran);
PJ6 (R.W. Knudsen ; Just Pomegranate; Knudsen & Sons,
Inc., Chico, CA); PJ7 (Aromaproduct Ltd., Product of
Georgia; distributed by Tamani, Inc., New York, NY).
Starches used were: PURE-DENT® B815 Corn Starch NF,
PURE-DENT® B816 Corn Starch USP, Spress® B825 Prege-
latinized corn starch NF, Spress® B820 Pregelatinized corn
starch NF, INSTANT PURE-COTE™ B792 Food starch-
modified, INSCOSITY™ B656 Food starch-modified
(Grain Processing Corporation, Muscatine, IN); PURITY®
21 corn starch NF and PURITY®  826 corn starch NF
(National Starch and Chemical Company, Bridgewater,
NJ); Remyline AX-DR Waxy rice starch and Remy DR
native rice starch, medium grind (A&B Ingredients, Fair-
field, NJ); ARGO® corn starch (Best Foods Division, CPC
International Inc., Engelwood Cliffs, NJ); STALEY® pure
food powder starch (Tate & Lyle, Decatur, IL); STARCH
1500 pregelatinized starch NF (Colorcon, West Point,
PA). The following polymers were used: polyethylene gly-
cols (PEG) 1000 NF, 1500 NF and 8000 NF; and hydrox-
ypropyl methylcellulose, 50 cps, USP (Spectrum, New
Brunswick, NJ); Carbopol 974P-NF (B. F. Goodrich Co.,
Cleveland, OH); Carbophil, Noveon AA1 (Noveon, Inc.,
Cleveland OH); and Pharmaburst B2 (SPI Pharma, New
Castle, DE). Fattibase was from Paddock Laboratories,
Inc., Minneapolis, MN.
Recombinant proteins employed were: HIV-1 IIIB gp120,
biotinyl-HIV-1 IIIB gp120, CD4, and biotinyl-CD4
(ImmunoDiagnostics, Inc., Woburn, MA); HIV-1 IIIB BaL
gp120 and FLSC (a full length single chain protein con-
sisting of BaL gp120 linked with the D1D2 domains of
CD4 by a 20 amino acid linker) (produced in transfected
293T cells [20]). Phycoerythrin (PE)-labeled streptavidin
was from R & D Systems, Minneapolis, MN. Biotinylated
Galanthus nivalis lectin was from EY Laboratories, Inc. San
Mateo, CA. Rabbit antibodies to synthetic peptides from
gp120 (residue numbering as in reference [21]) were pre-
pared as described [21]. Monoclonal antibodies (mAb)
588D, specific for the CD4 binding site, and 9284, specific
for the gp120 V3 loop, were from Dr. S. Zolla-Pazner and
NEN Research Products, Du Pont, Boston, MA, respec-
tively. A "generic" version of the nonnucleoside HIV-1
reverse transcriptase inhibitor TMC-120 [22] was synthe-
sized by Albany Molecular Research, Inc., Albany, NY, and
used in control experiments at a final 5 µM concentration.
Pelletted, 1000-fold concentrates of HIV-1 IIIB (6.8 × 1010
virus particles/ml) and BaL (2.47 × 1010 virus particles/
ml) were from Advanced Biotechnologies, Inc., Colum-
bia, MD. Primary HIV-1 isolates, MT-2 cells, HeLa-CD4-
LTR-β-gal and U373-MAGI-CCR5E cells (both contrib-
uted by Dr. Michael Emerman) and Cf2Th/synCCR5 cells
(contributed by Dr. Tajib Mirzabekov and Dr. Joseph
Sodroski) were obtained from the AIDS Research and Ref-
erence Reagent Program operated by McKessonBMC Infectious Diseases 2004, 4:41 http://www.biomedcentral.com/1471-2334/4/41
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BioServices Corporation, Rockville, MD. CEMx174
5.25M7 cells, transduced with an HIV-1 long terminal
repeat (LTR)-green fluorescent protein and luciferase
reporter construct, expressing CD4 and CXCR4 and CCR5
coreceptors [23], were obtained from Dr. Cecilia Cheng-
Mayer. The cells were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS), 1 µg/
ml puromycin and 200 µg/ml G418. These cells are suita-
ble for titration of both X4 and R5 HIV-1 isolates and for
determining the effectiveness of anti-HIV-1 drugs with
reliable reproducibility. This is impossible to accomplish
by using peripheral blood mononuclear cells (PBMCs)
because of their variations in susceptibility to HIV-1 infec-
tion among cells derived from distinct individuals [24-
26]. PBMCs were isolated from HIV-1 negative donors as
described [27].
Formulations
In attempts to separate gp120-CD4 binding inhibitory
activity from most other ingredients of PJ, 200 mg of dis-
tinct starch preparations were added per ml of PJ1. After
mixing for 1 h at 20°C, excess juice was decanted, and the
pellets resuspended in 1 ml of distilled water. Based on
results of enzyme linked immunosorbent assays (ELISA),
PURITY® 21 corn starch, NF grade (S21) was selected for
further studies, and the corresponding PJ complex was
designated as PJ-S21. PJ-S21 was freeze dried and used to
prepare the following formulations: PEG suppositories
(50% PJ-S21, 45% PEG 1000, 5% PEG 1500); Fattibase
suppositories (50% PJ-S21, 50% Fattibase); and mucoad-
hesive instantly dispersible tablets (50% PJ-S21, 20%
HPMC, 20% Pharmaburst, 7.5% Carbopol 974P and
2.5% Carbophil).
Enzyme linked immunosorbent assays (ELISA)
Inhibition of infection by HIV-1 IIIB and BaL, respec-
tively, was determined relying on a β-galactosidase read-
out system [18]. The enzyme was quantitated with a
Galacto-Light Plus System chemiluminescence reporter
assay (Applied Biosystems, Foster City, CA) using a Micro-
light ML 2250 luminometer (Dynatech Laboratories, Inc.,
Chantilly, VA). To measure virucidal activity, virus was
separated from excess inactivating agent by centrifugation
and/or precipitation with PEG 8000 [18,19]. Serial dilu-
tions of the treated virus were assayed for infectivity as
described above. Dose response curves (i.e. luminescence
vs. dilution) for treated and control viruses were obtained,
and the percentages of virus inactivation were calculated
[19]. To determine inhibition of infection by primary
HIV-1 strains, CEMx174 5.25 M7 cells were incubated
with 100 × TCID50 of primary HIV-1 strains in the absence
or presence of PJ-S21 at graded concentrations for 3 days
at 37°C. The experiments were done in triplicate. Infec-
tion was quantitated by measuring luciferase activity [23]
using a kit from Promega (Madison, WI) in an Ultra 384
luminometer (Tecan, Research Triangle Park, NC).
CD4-HIV-1 gp120 binding and its inhibition were meas-
ured by ELISA. Wells of 96-well polystyrene plates
(Immulon II, Dynatech Laboratories, Inc., Chantilly, VA)
were coated with 100 ng/well of either gp120 IIIB or
gp120 BaL, and post-coated as described [16]. Dilutions
of PJs and of PJ-S21, respectively, in 0.14 M NaCl, 0.01 M
Tris, 0.02% sodium merthiolate, pH 7.0 (TS) containing
100 µg/ml bovine serum albumin (BSA) were added to
the wells for 1 h at 37°C. The wells were washed 5 × with
TS. Biotinyl-CD4 (1 µg/ml) in TS-1% gelatin was added to
the wells for 5 h at 37°C. After washing 1 × with TS-0.1%
Tween 20 and 5 × with TS, horseradish peroxidase (HRP)-
streptavidin (0.625 µg/ml; Amersham, Arlington Heights,
IL) in TS-2% gelatin-0.05% Tween 20 was added. After 30
min at 37°C, the wells were washed 4 × with TS-0.1%
Tween 20 and 2 × with TS. Bound HRP was detected using
a kit from Kirkegaard and Perry Laboratories Inc. (Gaith-
ersburg, MD) and the absorbance (A) read at 450 nm. A
in the absence of inhibitors was 1.0 to 1.5, and 0 to 0.005
in the absence of biotinyl-CD4. In an alternative assay,
CD4 (500 ng/ml) was mixed with biotinyl-gp120 (1 µg/
ml) in the presence or absence of inhibitors for 30 min at
20°C. Serial dilutions of the mixtures were added to wells
coated with the anti-CD4 mAb OKT 4 (Ortho-Clinical
Diagnostics, Rochester, NY) and captured biotinyl-gp120
was detected with HRP-streptavidin as described above.
To measure binding to gp120 of antibodies to gp120 pep-
tides, the respective rabbit antisera were diluted 50-fold in
a mixture of FBS and goat serum (9:1) containing 0.1%
Tween 20 (pH 8.0) and added to gp120 wells. Bound IgG
was detected with HRP labeled anti-rabbit IgG (Sigma, St.
Louis, MO; 1 µg/ml in TS-10% goat serum-0.1% Tween
20). A cell-based ELISA was used to measure the blocking
of CCR5 binding sites on HIV-1 BaL gp120 by PJ and PJ-
S21, respectively [20]. Briefly, FLSC (125 ng/ml) in the
absence or presence of graded amounts of inhibitors was
added to Cf2Th/synCCR5 cells fixed with 5% formalde-
hyde in wells of 96-well plates. After 1 h at 37°C, bound
FLSC was detected with mAb M-T441 (125 ng/ml; Ancell,
Bayport, MN) specific for the CD4 D2 domain, followed
sequentially by biotinylated anti-mouse IgG and HRP-
streptavidin.
Results
Anti-HIV-1 activity of pomegranate juice
Serial twofold dilutions of juices [apple, black cherry,
blueberry, coconut milk, cranberry, elderberry, grape
(red), grapefruit, honey, lemon, lime, pineapple, pome-
granate and red beet (10% reconstituted dry powder)]
were assayed for inhibition of infection by HIV-1 IIIB of
cells expressing the CD4 and CXCR4 receptors and core-
ceptors. Most juices (4-fold diluted) had no inhibitoryBMC Infectious Diseases 2004, 4:41 http://www.biomedcentral.com/1471-2334/4/41
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activity, except blueberry, cranberry, grape and lime juice,
respectively [endpoints for 50% inhibition of infection
(ED50) between 1/16 and 1/64]. Consistently, PJs from
distinct geographical areas had the highest inhibitory
activity (Fig. 1; blue shaded area). Since HIV-1 viruses uti-
lizing CCR5 as coreceptor (=R5 viruses) are predomi-
nantly transmitted sexually [3,28], it was important to test
whether PJ can inhibit not only infection by HIV-1 IIIB, a
virus utilizing CXCR4 as coreceptor (=X4 virus), but also
infection by an R5 virus, HIV-1 BaL. Results in Fig. 1 (red
shaded area) show that infection by the latter virus is also
inhibited, albeit less effectively than that by HIV-1 IIIB.
Blocking virus entry is a primary target for microbicide
development [3,8-11]. Therefore, it was of interest to
determine whether or not PJ inhibited the binding of the
HIV-1 envelope glycoprotein gp120 to CD4, the common
receptor for both X4 and R5 viruses. Pretreatment of both
gp120 IIIB and BaL by PJ inhibited subsequent binding of
soluble labeled CD4 (Fig. 2). This suggested that one or
more PJ ingredients bound strongly or irreversibly to the
CD4 binding site on gp120. These results, obtained in an
ELISA using gp120 immobilized on polystyrene plates,
were confirmed in another assay in which both gp120 and
CD4 were in soluble form (data not shown). In reverse
experiments, pretreatment of CD4 with PJ failed to block
subsequent gp120 binding. Other juices having anti-HIV-
1 activity (blueberry, cranberry, grape and lime) failed to
block gp120-CD4 binding.
To delineate sites on gp120 blocked by the PJ inhibitor(s),
the inhibitory effect of PJ on binding to gp120 IIIB of anti-
bodies to peptides derived from the amino acid sequence
of gp120 was studied. The binding of antibodies to pep-
tides (102–126), (303–338), (306–338), (361–392),
(386–417), (391–425), (411–445) and (477–508) was
significantly (≥ 50%) inhibited (Fig. 3). The binding to
gp120 IIIB of monoclonal antibodies 9284 and 588D,
specific for the gp120 V3 loop (residues 303 – 338) and
the CD4 binding site, respectively [29,30] was each inhib-
ited by 97%. Some of the relevant peptides contain resi-
dues involved in CD4 binding [31-33] while all discerned
peptides include residues involved in coreceptor binding
[34-39]. The locations of the peptides and of residues
involved in receptor/coreceptor binding on the X-ray crys-
tallographic structure of gp120 are shown in Fig. 4. These
results suggest that the PJ inhibitor(s) may also block
gp120-coreceptor binding. This will be addressed
subsequently.
Separation of anti-HIV-1 inhibitor(s) from pomegranate 
juice
PJ is intensely colored. Therefore, it cannot be directly for-
mulated into a microbicide since it would stain clothing,
which is unacceptable. Attempts were made to separate or
Inhibition of HIV-1 infection of HeLa-CD4-LTR-β-gal and  U373-MAGI-CCR5E cells, respectively, by pomegranate juice  (PJ) Figure 1
Inhibition of HIV-1 infection of HeLa-CD4-LTR-β-gal 
and U373-MAGI-CCR5E cells, respectively, by pome-
granate juice (PJ). Blue shaded area = HIV-1 IIIB; red 
shaded area = HIV-1 BaL. Four distinct PJs (PJ1 to PJ4) were 
tested. Infection was monitored by measuring β-galactosi-
dase.
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Inhibition of CD4 binding to recombinant gp120 IIIB and BaL,  respectively, by pomegranate juice (PJ) Figure 2
Inhibition of CD4 binding to recombinant gp120 IIIB 
and BaL, respectively, by pomegranate juice (PJ). 
Recombinant gp120 coated wells were incubated with dilu-
tions of the PJ for 1 h at 37°C. After removal of the juice, and 
washing the wells, biotinyl-CD4 was added, and its binding to 
the wells was measured by ELISA.
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isolate the active ingredient(s) from PJ. After striving inter-
mittently for over four years to accomplish this, it was dis-
covered that the inhibitor(s) of gp120-CD4 binding can
be adsorbed effectively (≥ 99%) onto a selected brand of
corn starch (Fig. 5), resulting in a nearly colorless product,
designated as PJ-S21. PJ-S21, suspended in water or
unbuffered 0.14 M NaCl had a pH of 3.2, compatible with
the acidic vaginal environment in which it would remain
stabile after application (see below). Inhibitors of gp120-
CD4 binding could be eluted from PJ-S21 by extraction
with ethanol/acetone 6:4. Drying of the extract followed
by gravimetry indicated that the extract contained 3.17 mg
solids per gram of PJ-S21.
PJ-S21, to the same extent as the original PJ, inhibited the
binding of gp120 IIIB-CD4 complexes to cells expressing
CXCR4, as determined by flow cytometry (Fig. 6). Simi-
larly, binding of a gp120 BaL-CD4 fusion protein to cells
expressing CCR5 was blocked by PJ and PJ-S21, as detem-
ined by a cell based ELISA [20]; (Fig. 7). Thus, PJ-S21 is an
inhibitor of both X4 and R5 virus binding to the cellular
receptor CD4 and coreceptors CXCR4/CCR5. PJ-S21 also
inhibited gp120 binding to PBMCs as determined by flow
cytometry (Fig. 8). To confirm that PJ-S21 functions as a
virus entry inhibitor, the complex was added to cells at
time intervals before and after infection of cells by HIV-1
IIIB and BaL, respectively. Results shown in Fig. 9 demon-
strate that PJ-S21 interferes with early steps of the virus
replicative cycle.
To be considered as a topical microbicide, PJ-S21 must be
formulated to withstand storage in a tropical
Inhibition by pomegranate juice (PJ) of binding to gp120 of  antibodies to synthetic peptides from the gp120 sequence Figure 3
Inhibition by pomegranate juice (PJ) of binding to 
gp120 of antibodies to synthetic peptides from the 
gp120 sequence. Wells of polystyrene plates coated with 
gp120 IIIB were incubated with 4-fold diluted PJ for 1 h at 
37°C. After removal of PJ, the wells were washed, and 50-
fold diluted anti-peptide antisera [21] were added. Bound IgG 
was quantitated by ELISA. PJ was not added to control wells. 
Decreases of absorbance, as compared to the respective 
control wells, are plotted.
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Location on the gp120 structure of segments corre-
sponding to anti-peptide antibodies whose attach-
ment to gp120 is inhibited by ≥ 50 % in the presence 
of pomegranate juice (red) and of amino acid resi-
dues involved in CD4 and CXCR4/CCR5 coreceptor 
binding, respectively. Green, portions of the structure 
corresponding to anti-peptide antibodies whose attachment 
to gp120 is not significantly inhibited by PJ. The CD4 domains 
and the antigen-binding fragment of a neutralizing antibody 
were excised from the structure of the gp120-CD4-antibody 
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indicated.
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environment. Accelerated thermal stability studies
revealed that a water suspension of PJ-S21 maintained
only 4, 11, and 33%, respectively, of its original activity
(measured by inhibition of gp120-CD4 binding) when
stored for 30 min at 60°C, and one week at 50°C or 40°C.
On the other hand, a dried PJ-S21 powder remained fully
active after storage at 50°C for 12 weeks (the longest time
used in the evaluation). Consequently, anhydrous formu-
lations should be preferred for further development.
Three such formulations were prepared: two kinds of sup-
positories, melting at 37°C, and a tablet (for composi-
tions see Methods section). The inhibitory activity of PJ-
S21 was fully preserved after 12 weeks storage at 50°C
within tablets, and at 30°C within the suppositories (the
highest temperature considered to prevent melting). Data
showing the inhibition of infection by HIV-1 IIIB and BaL
respectively, by PJ-S21 and its formulations (except the
tablets which also contain anti-HIV-1 inhibitors other
than PJ-S21, i.e. Carbopol 974P [18]) are summarized in
Fig. 10. Their inhibitory activities against HIV-1 IIIB and
BaL were similar, unlike the inhibitory activities of the
original PJs (Fig. 1). These formulations were also
virucidal, albeit at concentrations higher than those suffi-
cient for inhibition of infection. These experiments also
revealed that PJ-S21 was not cytotoxic under the experi-
mental conditions used. The inhibitory/virucidal activi-
ties were maintained in the presence of seminal fluid (SF)
at a 1:1 (w/w) ratio of SF to PJ-S21; (data not shown).
A microbicide can be considered potentially successful,
only if it has antiviral activity against primary virus iso-
lates belonging to distinct virus clades and phenotypes.
PJ-S21 meets this requirement since it inhibited infection
by primary HIV-1 strains of all clades tested having R5 and
X4R5 (= dual-tropic) phenotypes (Table 1).
Discussion
Pomegranates have been venerated for millennia for their
medicinal properties and considered sacred by many of
Adsorption onto corn starch of gp120-CD4 binding inhibi- tor(s) from pomegranate juice (PJ) Figure 5
Adsorption onto corn starch of gp120-CD4 binding 
inhibitor(s) from pomegranate juice (PJ). Corn starch 
(PURITY® 21, NF grade; 200 mg/ml) was added to PJ prefil-
tered to remove particulates. After mixing for 1 h at ≈20°C, 
the starch was allowed to settle and the supernatant fluid 
was removed by aspiration. The pellets, resuspended (200 
mg/ml) in phosphate buffered saline, and the supernatant flu-
ids were tested at serial dilutions for inhibition of CD4 bind-
ing to gp120 IIIB as described in the legend for Fig. 2. The 
inhibitory activity of the resuspended pellet against gp120 
BaL-CD4 binding was then confirmed. Control starch did not 
inhibit gp120-CD4 binding.
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Inhibition by pomegranate juice (PJ) and PJ-S21, respectively,  of gp120 IIIB-CD4 complex binding to cells expressing  CXCR4 coreceptors Figure 6
Inhibition by pomegranate juice (PJ) and PJ-S21, 
respectively, of gp120 IIIB-CD4 complex binding to 
cells expressing CXCR4 coreceptors. HIV-1 IIIB gp120 
(5 µg) and biotinyl-CD4 (2.5 µg) were added to 100 µl phos-
phate buffered saline (PBS) containing 100 µg/ml bovine 
serum albumin (BSA) (PBS-BSA) and PJ (final 3-fold dilution) 
or PJ-S21 (67 mg; corresponding to 212 µg solids from PJ 
adsorbed onto starch). After 1 h at 20°C, the respective mix-
tures were added to 106 MT-2 cells. After 30 min, the cells 
were washed 3 times with PBS-BSA and PE-streptavidin (a 
fluorescent label specific for biotin; 0.1 µg) was added. After 
20 min, the cells were washed and fixed by 1% formaldehyde 
in PBS. Flow cytometry analysis was performed in a FACS-
Calibur flow cytometer (Becton Dickinson Immunocytomet-
ric Systems, San Jose, CA). The median relative fluorescence 
values for cells exposed to gp120-CD4; gp120-CD4 + PJ; 
gp120-CD4 + PJ-S21; and control cells were: 13.7; 4.0; 4.3; 
and 2.1, respectively.
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the world's major religions. In deference to pomegranates,
the British Medical Association and several British Royal
Colleges feature the pomegranate in their coat of arms.
The Royal College of Physicians of London adopted the
pomegranate in their coat of arms by the middle of the
16th Century [40]. The best known literary reference to the
contraceptive power of pomegranate seeds is classical
Greek mythology. Persephone (IIερσεφονη) had eaten six
pomegranate kernels (from which juice is derived) while
in the Underworld and for that many months the land
remained infertile during the Fall and Winter (Fig. 11).
Ironically, this report shows that pomegranate juice con-
tains HIV-1 entry inhibitors targeted to the virus envelope
corresponding to a class of anti-retroviral drugs still scarce
in development [41].
Inhibition by pomegranate juice (PJ) and PJ-S21, respectively  of FLSC binding to CCR5 expressing Cf2Th/synCCR5 cells Figure 7
Inhibition by pomegranate juice (PJ) and PJ-S21, 
respectively of FLSC binding to CCR5 expressing 
Cf2Th/synCCR5 cells. FLSC is a chimeric recombinant 
protein consisting of gp120 BaL linked with D1D2 domains of 
CD4. The inhibitory effect was quantitated using a cell-based 
ELISA [20]. The starting concentration of PJ-S21 was 200 mg/
ml, corresponding to 634 µg/ml solids adsorbed onto starch 
from PJ.
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Inhibition by PJ-S21 of biotinyl-gp120 IIIB binding to periph- eral blood mononuclear cells (PBMCs) Figure 8
Inhibition by PJ-S21 of biotinyl-gp120 IIIB binding to 
peripheral blood mononuclear cells (PBMCs). HIV-1 
IIIB biotinyl-gp120 (5 µg) was added to 100 µl of PBS-BSA 
containing graded quantities of PJ-S21. After 1 h at 20°C, the 
respective mixtures were added to 106 PBMCs. After 30 min 
the cells were washed 3× with PBS-BSA and PE-streptavidin 
(0.1 µg was added). Subsequently the procedures described 
in the legend to Fig. 6 were used. The median relative fluo-
rescence values for control cells and cells exposed to bioti-
nyl-gp120 in the absence and presence of PJ-S21 (100, 6.25 
and 3.12 mg/ml) were 4.1, 81.31, 12.2, 35.2 and 50.0 respec-
tively. 100 mg of PJ-S21 corresponds to ≈ 320 µg solids 
adsorbed from PJ onto starch.
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Table 1: Inhibitory activity of PJ-S21 on infection by primary HIV-1 strains
Primary strain Subtype, Coreceptor use ED50* mg/ml ED90* mg/ml
92RW008 A, R5 0.50 ± 0.05 2.76 ± 0.28
94UG103 A, X4R5 1.42 ± 0.54 3.42 ± 0.98
92US657 B, R5 0.62 ± 0.11 2.86 ± 0.33
93IN101 C, R5 3.56 ± 1.10 8.87 ± 2.55
93MW959 C, R5 1.02 ± 0.19 3.54 ± 0.90
92UG001 D, X4R5 0.62 ± 0.17 2.94 ± 0.85
93THA051 E, X4R5 0.86 ± 0.01 4.09 ± 0.08
93BR020 F, X4R5 4.25 ± 0.78 8.31 ± 1.04
RU570 G, R5 0.42 ± 0.09 1.54 ± 0.16
BCF02 Group O, R5 0.59 ± 0.29 3.92 ± 0.27
* ED50(90) = effective dose(s) of PJ-S21 for 50% (90%) inhibition of infection. One gram of PJ-S21 contains approximately 3.2 mg of the inhibitors 
adsorbed to starch from pomegranate juice.BMC Infectious Diseases 2004, 4:41 http://www.biomedcentral.com/1471-2334/4/41
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PJ contains several ingredients [42,43] which, isolated
from natural products other than PJ, were reported to
have anti-HIV activity, for example: caffeic acid [44],
ursolic acid [45], catechin and quercetin [46,47]. How-
ever, these compounds, in purified form, obtained com-
mercially, did not block (at 200 µg/ml) gp120-CD4
binding as measured by the ELISA described above and
did not adsorb to corn starch, unlike the entry inhibitor(s)
from PJ. In fact, the supernatant after treatment of PJ with
starch, and removal of the entry inhibitors, retained anti-
HIV-1 activity and also inhibited infection by herpes virus
type 1, unlike the HIV-1 entry inhibitors which adsorbed
onto starch. Thus, the antiviral activities in the superna-
tant appeared to be non-specific, and probably similar to
those of extracts from pomegranate rind [48,49], and were
not characterized further. Additional information [50-53]
has revealed that the findings apply to crude extracts from
pomegranate rind prepared at elevated temperatures
under conditions which destroy the HIV-1 entry inhibitor
described here.
The inhibitor(s) interfering with gp120 binding to CD4
(Fig. 2 and 5) blocked additional sites on gp120 (Fig. 3)
involved in interaction with the CXCR4/CCR5 corecep-
tors (Fig. 4, 6 and 7). This was not completely expected
and can be explained either by the presence of multiple
inhibitors with distinct or overlapping specificities in PJ-
S21 or by induction of gp120 conformational changes
[54] resulting in blockade of both CD4 and CXCR4/CCR5
binding sites on gp120. Similar effects have been noticed
for other small molecule inhibitors [55]. Simultaneous
blocking of more than a single site on HIV-1 involved in
virus entry is expected to increase the effectiveness of
candidate microbicides [11]. The target sites for the
inhibitor(s) are likely to be located within the protein
moiety of gp120 since binding of labeled Galanthus nivalis
lectin (specific for terminal mannose residues [56]; and
other lectins to gp120 oligosaccharides was not dimin-
ished in the presence of PJ or PJ-S21 (data not shown).
Blocking of CD4 binding sites on HIV-1 gp120 by mono-
clonal antibodies or a CD4-IgG2 recombinant protein has
Inhibition of HIV-1 IIIB or BaL replication depends on the  time of PJ-S21 addition pre- or post-infection Figure 9
Inhibition of HIV-1 IIIB or BaL replication depends 
on the time of PJ-S21 addition pre- or post-infection. 
For comparison, the inhibition of infection by the nonnucleo-
side reverse transcriptase inhibitor TMC-120, added to cells 
at distinct intervals after HIV-1, was determined (dotted 
lines). Virus infection was measured by quantitation of β-
galactosidase.
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HIV-1 inhibitory and virucidal activity of PJ-S21 and its  formulations Figure 10
HIV-1 inhibitory and virucidal activity of PJ-S21 and 
its formulations. Inhibition of infection by HIV-1 IIIB and 
BaL, respectively, was determined as described in the legend 
for Fig. 1. To measure virucidal activity, the respective 
viruses were mixed with graded quantities of PJ-S21 for 5 
min at 37°C. After low speed centrifugation, the viruses 
were separated by precipitation with PEG 8000 and centrifu-
gation. The resuspended pellets and control untreated 
viruses were serially diluted, and the dilutions assayed for 
infectivity. The concentration range given on the abscissa 
corresponds to 0.31 – 1,268 µg solids adsorbed from PJ to 
starch.
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been shown to be sufficient to inhibit HIV-1 infection of
human cervical tissue ex vivo [11] and in preventing virus
transmission to macaque monkeys when applied vagi-
nally [57]. Therefore, it seems likely that PJ-S21 will be
similarly effective, an expectation which remains to be
confirmed.
The application of PJ-S21 as a topical anti-HIV-1 microbi-
cide requires reasonable uniformity among batches pro-
duced at distinct times and locations. Similarities in
gp120-CD4 binding inhibitory activity among distinct
freshly prepared and commercial juices stored for
unknown periods (Fig. 2) suggest that this should be fea-
sible. Pasteurization of juice for 30 seconds at 85°C
resulted in complete loss of inhibitory activity. A commer-
cial PJ concentrate exposed to 61°C, and two other con-
centrates, presumably prepared by evaporation at elevated
temperatures, had no or drastically diminished activity.
The gp120-CD4 inhibitory activity from PJ3 (juice with
fructose and citric acid added), failed to bind to starch.
Separate experiments revealed that these compounds
interfere with inhibitor binding to corn starch. Therefore,
PJs intended for production of the PJ-S21 complex must
be sterilized by filtration and be free of additives.
Particular attention must be devoted to the selection of
starch, a pharmaceutical excipient generally used in vagi-
nal formulations [58], for effective binding of the virus
entry inhibitors from PJ. Among a dozen starches tested,
the best results have been obtained with S21. With other
brands, the adsorption of the inhibitors was either incom-
plete or their binding did not result in a complex having
activity in the ELISA measuring gp120-CD4 binding inhi-
bition (ARGO®  corn starch), presumably, because of
irreversible binding of the PJ inhibitors. Interestingly,
there are only a few references available regarding the use
of starch as an adsorbent for different compounds: flavors
[59,60], dyes [61-63], low-molecular mass saccharides
[64], lipids [65,66], proteins [67] and iodine [68].
The intended dose of PJ-S21 for vaginal application is 1.0
to 1.5 g, (= 3.17 – 4.76 mg solids from PJ adsorbed onto
starch) i.e. ≥ 100-fold higher than the dose needed for
blocking HIV-1 infection in vitro (Fig. 10, Table 1), and
thus expected to meet requirements for likely in vivo pro-
tection against vaginal challenge [69]. This quantity of PJ-
S21 is produced from 5 to 7.5 ml of PJ, i.e. ≤ 5% of a single
(150 ml) serving of juice, attesting to the safety, feasibility
and economy of this proposed candidate topical
microbicide.
In an alternative approach to formulation development,
PJ-S21 can be incorporated into a water dispersible film
(similar to the widely available "breath control" strips) or
into water dispersible sponges [70] which are converted
Persephone (IIερσεφονη) holding a pomegranate Figure 11
Persephone (IIερσεφονη) holding a pomegranate. In 
Greek mythology she had eaten seeds of the fruit and conse-
quently was condemned to remain in Hades, the Under-
world, for six months of every year. Derived from a painting 
of Dante Gabriel Rossetti in the Collection of the Tate Gal-
lery in London.BMC Infectious Diseases 2004, 4:41 http://www.biomedcentral.com/1471-2334/4/41
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into a gel following topical application [19]. Each of the
above formulations would meet the following require-
ments: (1) minimization of waste disposal problems
associated with the use of applicators needed for delivery
of microbicidal gels/creams; (2) simplicity; (3) small
packaging and discretion related to purchase, portability
and storage; (4) low production costs; (5) amenability to
industrial mass production at multiple sites globally and
(6) potential application as rectal microbicides. Further-
more, it would remain possible to produce for local use
PJ-S21 based gel formulations with a limited shelf life,
avoiding the costs of producing dry PJ-S21 powders via
appropriate low temperature drying processes. Whichever
of these formulations is selected, adequate quality control
will be needed to assure uniform anti-HIV-1 activity of the
final product(s) and to establish reproducible conditions
for manufacture.
Conclusions
PJ-S21 can be classified as an AAAA candidate microbi-
cide: Acceptable; Accessible; Affordable; and Accelerative
in transition from development to marketing. Thus, PJ-
S21 would be expected to circumvent some problems
associated with antiretroviral drugs and possibly some of
the other candidate microbicides, i.e. uncertainty related
to potential side effects, investment and time needed to
establish inexpensive large scale production, and monop-
oly of supply.
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